Warfarin Outcomes in China
The trial was conducted at five centres representing multiple hospital levels in Hunan Province, China, from March 2021 to March 2023. The dominant warfarin management model in China is usual care, where physicians handle dose adjustments…
1 sources - 4 claims
The trial was conducted at five centres representing multiple hospital levels in Hunan Province, China, from March 2021 to March 2023. The dominant warfarin management model in China is usual care, where physicians handle dose adjustments for large patient panels with limited capacity for patient education. Ischaemic stroke attributable to warfarin occurs in 5.23% of Chinese patients versus a global average of 2.07%, and intracranial haemorrhage in 2.94% versus 0.63% globally. High clinical workloads leave physicians in China with limited capacity for patient education in warfarin management.